m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03261)
Name
MCC950
Synonyms
MCC950; 210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H24N2O5S
InChI
1S/C20H24N2O5S/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23)
InChIKey
HUUSXLKCTQDPGL-UHFFFAOYSA-N
PubChem CID
9910393
TTD Drug ID
D09FGL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Caterpiller protein 1.1 (NLRP3)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Caterpiller protein 1.1 (NLRP3) is a therapeutic target for MCC950. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCC950 through regulating the expression of Caterpiller protein 1.1 (NLRP3). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Caterpiller protein 1.1 (NLRP3) is a therapeutic target for MCC950. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MCC950 through regulating the expression of Caterpiller protein 1.1 (NLRP3). [2], [3]
References
Ref 1 Total Flavones of Abelmoschus manihot Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent m(6)A Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling. Front Pharmacol. 2021 Jul 15;12:667644. doi: 10.3389/fphar.2021.667644. eCollection 2021.
Ref 2 National Cancer Institute Drug Dictionary (drug name BMS-986299).
Ref 3 RNA m6A reader YTHDF1 facilitates inflammation via enhancing NLRP3 translation. Biochem Biophys Res Commun. 2022 Aug 6;616:76-81. doi: 10.1016/j.bbrc.2022.05.076. Epub 2022 May 24.